Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (42)

2023

  1. JNK Activation in Alzheimer’s Disease Is Driven by Amyloid β and Is Associated with Tau Pathology

    ACS Chemical Neuroscience

  2. JNK3 Overexpression in the Entorhinal Cortex Impacts on the Hippocampus and Induces Cognitive Deficiencies and Tau Misfolding

    ACS Chemical Neuroscience, Vol. 14, Núm. 11, pp. 2074-2088

  3. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models

    Neurobiology of Disease, Vol. 183

2021

  1. Interictal amylin levels in chronic migraine patients: A case-control study

    Cephalalgia, Vol. 41, Núm. 5, pp. 604-612

  2. Microglia is associated with p-Tau aggregates in the olfactory bulb of patients with neurodegenerative diseases

    Neurological Sciences, Vol. 42, Núm. 4, pp. 1473-1482

  3. Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

2020

  1. A Spanish consensus on the use of safinamide for parkinson’s disease in clinical practice

    Brain Sciences, Vol. 10, Núm. 3

  2. CAV-2-Mediated GFP and LRRK2G2019S Expression in the Macaca fascicularis Brain

    Frontiers in Molecular Neuroscience, Vol. 13

  3. Erratum: A Spanish consensus on the use of safinamide for parkinson’s disease in clinical practice. (Brain sci. (2020) 10, 176)

    Brain Sciences

  4. Excess abdominal fat is associated with cutaneous allodynia in individuals with migraine: A prospective cohort study

    Journal of Headache and Pain, Vol. 21, Núm. 1

2019

  1. Amylin as a potential link between type 2 diabetes and alzheimer disease

    Annals of Neurology, Vol. 86, Núm. 4, pp. 539-551

  2. Cardiac sympathetic innervation in the MPTP non-human primate model of Parkinson disease

    Clinical Autonomic Research, Vol. 29, Núm. 4, pp. 415-425

  3. Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings

    Journal of Neurology, Vol. 266, Núm. 10, pp. 2396-2405

  4. Nanobiotechnology in parkinson’s disease

    Nanobiotechnology in Neurodegenerative Diseases (Springer International Publishing), pp. 177-208

2018

  1. Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies

    Acta Neuropathologica, Vol. 135, Núm. 6, pp. 877-886

  2. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

    Neurobiology of Disease, Vol. 118, pp. 64-75

2016

  1. Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems

    Maturitas, Vol. 84, pp. 25-31

  2. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

    Biomaterials, Vol. 110, pp. 11-23

2015

  1. Autonomic involvement in Parkinsonian carriers of PARK2 gene mutations

    Parkinsonism and Related Disorders, Vol. 21, Núm. 7, pp. 717-722

  2. Descripción de una serie de pacientes con diagnóstico de enfermedad priónica

    Neurologia, Vol. 30, Núm. 3, pp. 144-152